Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 251 - 300 out of 126,747

Document Document Title
WO/2017/171563A1
Improving the cognitive function of an animal by providing a composition containing beta-casein, wherein at least 75% by weight of the beta-casein is a beta-casein variant that does not produce BCM-7 on digestion in the gut of the animal.  
WO/2017/167180A1
The present invention provides a vortioxetine pamoic acid salt, which includes a crystal form, a solvate or an amorphous substance of the vortioxetine pamoic acid salt. The present invention provides a preparation method and use of the v...  
WO/2017/167897A1
The present invention relates to a composition comprising a phospholipid or a metabolic precursor or metabolite thereof, or a mixture thereof, for use in promoting, supporting or optimizing one or more of the following: (i) de novo myeli...  
WO/2017/167896A1
The present invention relates to a composition comprising one or more mineral nutrients selected from iron, zinc, calcium, phosphorus, copper, magnesium, iodine, manganese, chloride, potassium, sodium, selenium, chromium, and combination...  
WO/2017/167420A1
The present invention relates to a composition comprising at least one vitamin, for use in promoting, supporting or optimizing one or more of the following: (i) de novo myelination; (ii) brain structure; (iii) brain connectivity; (iv) in...  
WO/2017/168138A1
The present invention relates to the use of cannabidiol (CBD) in the treatment of Sturge Weber syndrome. CBD appears particularly effective in reducing all types of seizures and non-seizure symptoms in patients suffering with Sturge Webe...  
WO/2017/171594A1
The present disclosure relates to the use of negative allosteric modulators (NAMs) of the metabotropic glutamate receptor 5 (mGluR5) in the treatment of a mature brain damage, such as damage after stroke.  
WO/2017/165845A1
This disclosure relates to methods administering various compounds in conjunction with dextromethorphan to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan or dextrorphan and bupropion, hydroxyb...  
WO/2017/164084A1
Provided is a patch preparation which has a misuse prevention performance. The patch preparation comprises a support and a plaster, wherein the plaster contains 2-35 wt% of a solvent which has a vapor pressure of 1 kPa or greater at 20oC...  
WO/2017/165877A1
Disclosed is a method of treating Psychotic Depression, Suicidal Ideation, Disruptive Mood Dysregulation Disorder, Persistent Depressive Disorder (Dysthymia), Premenstrual Dysphoric Disorder, Substance/Medication-Induced Depressive Disor...  
WO/2017/164331A1
Provided is a low-cytotoxicity composition that can be applied to a drug delivery system enabling passage through the blood-brain barrier. A nanoparticle composition comprises nanoparticles to the surface of which a first substance and s...  
WO/2017/161402A1
A formulation and a method for treating, preventing, ameliorating or alleviating in a patient the symptoms of hangover, or of veisalgia, associated with a bout of excessive alcohol consumption are disclosed. More specifically, a formulat...  
WO/2017/162884A1
The present invention relates to a method for treating patients afflicted with non-aggressive or moderately aggressive amyotrophic lateral sclerosis (ALS) whose rate of change of the revised Amyotrophic Lateral Sclerosis Functional Ratin...  
WO/2017/164230A1
The present invention provides a phosphorylated SARM1 (Sterile alpha and TIR motif-containing protein 1) in which at least one Ser residue selected from the group consisting of position 54, position 548, and position 622 of SARM1 is phos...  
WO/2017/162870A1
Methods for improving active movement capacity in a subject experiencing muscle impaired or abnormal activity, and software products and computer systems for implementing such methods. A subject having impaired active movement capacity i...  
WO/2017/164173A1
Provided is a novel compound which has an excellent Aβ aggregation-inhibiting activity and is useful as a medicine. An imidazole compound represented by general formula (1) (wherein A, B and C may be the same as or different from one an...  
WO/2017/164172A1
Provided are a compound that is bioapplicable and amyloid-selective, and is useful as an amyloid oxidation catalyst applicable not only to aβ peptides but to other amyloids as well, and a preventive/therapeutic agent for amyloid-related...  
WO/2017/162168A1
The present invention relates to a salt form of (R)-methyl-2-(3-aminopiperidin-1-yl)-3-(2-cyanobenzyl)-4-car bonyl-3,4-dihydrothiophene[3,2-d]pyrimidine-6-carboxylic acid and a preparation method for the salt form. Also disclosed is a ph...  
WO/2017/162830A1
A process for preparing a modified heat-treated platelet pellet lysate, said process comprising the steps of: a) Providing a platelet pellet lysate, b) Heat-treating the platelet pellet lysate at a temperature of 55°C to 65°C during 20...  
WO/2017/165755A1
The invention relates to particular substituted fluorinated heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositi...  
WO/2017/165635A1
A method for treating a disease or disorder in a patient who is currently taking a cytochrome P450 inhibitor comprising administering to the patient a dose of pimavanserin or a pharmaceutical acceptable salt thereof, wherein the dose is ...  
WO/2017/161402A8
A formulation and a method for treating, preventing, ameliorating or alleviating in a patient the symptoms of hangover, or of veisalgia, associated with a bout of excessive alcohol consumption are disclosed. More specifically, a formulat...  
WO/2017/165806A1
Disclosed herein are compositions and methods for treating neuropathy, embodiments, HSV vectors are provided comprising nucleic acid molecules encoding neurotrophins, such as neurotrophin 3 (NT3).  
WO/2017/163101A1
Embodiments of the present invention disclose formulations comprising NAD for reducing sugar craving and methods of making and using the same. Embodiments of the invention also discloses dosage forms comprising the formulation of inventi...  
WO/2017/163203A1
It is here described a protein which is at least one SUMO protein, or a variant or a fragment thereof or a fusion protein comprising the same for use in the treatment of neurodegenerative and/or neurological disorders. In a further embod...  
WO/2017/164349A1
Provided is a medicinal composition comprising a stable PEG antihuman NGF antibody Fab' fragment wherein the formation of a degradation product, multimer, acidic analog, basic analog and insoluble foreign matters is suppressed. The medic...  
WO/2017/162674A1
The present invention relates to a compound of formula (I) wherein P1, P3, P4 and P5 are amino acid residues. The invention also relates to a compound of formula (I) for its use as a Caspase-2 inhibitor and for its therapeutical use. It ...  
WO/2017/165747A1
Compositions and methods for treating, inhibiting, and/or preventing pain, particularly neuropathic pain, are provided.  
WO/2017/165458A1
The invention is directed to methods for diagnosis and differentiation of neurodegenerative diseases (NDs), by quantifying miRNAs in bodily fluids.  
WO/2017/165237A1
Provided herein is a neural sleep circuit that includes: a first subtype of neurons in a preoptic area (POA) of the brain, wherein neurons of the first subtype (a) are gamma aminobutyric acidproducing (GABAergic), and (b) project to a tu...  
WO/2017/162536A1
Prodrugs of vortioxetine are provided  
WO/2017/157326A1
Provided is a nerve growth factor mutant, wherein same is an amino acid sequence as shown by any one of SEQ ID No: 3 to SEQ ID No: 21 in the sequence listing. The advantage of the nerve growth factor mutant lies in that the mutation of a...  
WO/2017/160864A1
The present invention includes a method of protecting or treating neural cells from degeneration comprising: identifying a neural cell in need of protection from at least one of radical oxidative stress, increased mitochondrial biogenesi...  
WO/2017/157325A1
The present invention relates to the field of biopharmaceuticals and provides a fusion protein comprising a nerve growth factor (NGF) and a preparation method and use thereof. The fusion protein has a general formula represented by A-B o...  
WO/2017/161370A1
Provided herein are alpha5-containing GABAA receptor agonists and pharmaceutical compositions and methods of treatment of cognitive and mood symptoms in neurodegenerative and neuropsychiatric disorders using them.  
WO/2017/157873A1
The present invention relates to a compound of formula (I) and to a pharmaceutically suitable acid addition salt thereof with a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1, for the treatment of cer...  
WO/2017/159484A1
[Problem] To provide an agent for inhibiting aggregation of tau and/or amyloid β. [Solution] A compound represented by formula (I) or a salt thereof. This compound is used in therapy, diagnosis, and symptom alleviation and in prevention...  
WO/2017/158093A1
The present invention relates to a nanoparticle composition comprising PLGA derivatives and a lipid. The composition is suitable for medical use. Particularly, the present invention relates to a delivery system for delivery of drugs, in ...  
WO/2017/161172A1
Provided herein are methods, compounds, and compositions for reducing expression of KEAP1 in animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate oxidative stress or a disease, disorder or ...  
WO/2017/160622A1
The present invention provides a method of treating a cognitive or neurodegenerative disease, comprising administering to a patient in need of such treatment an effective amount of (1r,1'R,4R)-4-methoxy-5"-methyl-6'-[5-(prop-1-yn-1-yl)py...  
WO/2017/160922A1
Disclosed herein are compounds of Formula (I), methods of synthesizing compounds of Formula (I), and methods of using compounds of Formula (I) as an analgesic.  
WO/2017/160925A1
Disclosed herein are compounds of Formulae (I), and (II), methods of synthesizing compounds of Formulae (I) and (II), and methods of using compounds of Formulae (I) and (II) as an analgesic.  
WO/2017/160552A1
Disclosed herein novel dopamine D3 receptor selective antagonists/partial agonists compounds with high affinity and metabolic stability useful for the treatment of psychiatric and neurological disorders and as research and diagnostic too...  
WO/2017/157929A1
The present invention relates to quinoline compounds of formula (I) wherein the variables are defined as in the claims and the description. The invention further relates to a pharmaceutical composition containing such compounds, to their...  
WO/2017/160864A8
The present invention includes a method of protecting or treating neural cells from degeneration comprising: identifying a neural cell in need of protection from at least one of radical oxidative stress, increased mitochondrial biogenesi...  
WO/2017/161137A1
The invention provides methods and compositions for treating a subject with a neurodegenerative disorder, where the subject has a sphingotype indicative that the subject is likely to respond to treatment with an activator of β-glucocere...  
WO/2017/159700A1
A non-tubular material for nerve regeneration induction use, which can be used for the regeneration of a damaged part in a nerve, and which comprises: (A) a crosslinked substance produced by crosslinking a low-endotoxin bioabsorbable pol...  
WO/2017/160711A1
The present disclosure relates to methods of treating at least one symptom of a mental disorder or disease of the central nervous system in a subject by modulating the amount of GABA produced in the subject's gut. The present disclosure ...  
WO/2017/158064A1
The present disclosure provides for methods for treating a subject having a disease or disorder associated with the accumulation of amyloid beta, comprising administering to the subject a BACE inhibitor and an antibody or antigen-binding...  
WO/2017/161017A1
The invention provides -opioid receptor agonists that are analgesic agents and that promote diminished side effects relative to a comparably effective dose of morphine. The side effects that are absent or attenuated include one or more o...  

Matches 251 - 300 out of 126,747